Laskin W B, Fetsch J F, Miettinen M
Department of Pathology, Northwestern University Medical School, Chicago, IL, USA.
Hum Pathol. 2000 Oct;31(10):1230-41. doi: 10.1053/hupa.2000.18474.
In contrast with the myxoid variant of neurothekeoma (nerve sheath myxoma), evidence of neurosustentacular (NS) differentiation in the so-called cellular and mixed (intermediate) variants of neurothekeoma remains controversial. In this study, we selected 22 tumors coded as neurothekeoma or nerve sheath myxoma from the Soft Tissue Registry of the AFIP. Each tumor was histologically subtyped as either a myxoid/hypocellular neurothekeoma (MN) (N = 11) or as a "cellular" or "mixed" (intermediate) neurothekeoma variant (C&MV) (n = 11) and analyzed immunohistochemically. The MNs were composed of small, cytologically bland cells arranged in a loose cellular network or in files within highly myxomatous nodules delineated by dense collagen. The tumors showed clear-cut evidence of NS differentiation by exhibiting consistent immunoreactivity for S-100 protein (11 of 11 cases) and low-affinity nerve growth factor receptor, p75(NGFR), (NGFR) (10 of 10), and variable reactivity for glial fibrillary acidic protein (GFAP) (10 of 11) and CD57 (Leu-7) (5 of 9). They also showed pericellular collagen type IV (CIV) expression (9 of 9), scattered intralesional CD34-positive spindled cells (10 of 10), epithelial membrane antigen (EMA)-positive spindled cells located within the adjacent dense collagen (8 of 11), and immunoreactivity for alpha-smooth muscle actin (SMA) (3 of 10) and calponin (4 of 9). In 4 cases, scattered intralesional neuraxons were detected by the Bodian histochemical method or immunohistochemically with anti-neurofilament protein. The tumors had a male-to-female ratio of 6:5, a peak incidence in the 4th decade of life, and an anatomic distribution that included the upper and lower limbs and back. The C&MVs included 9 "mixed" and 2 "cellular" variants. C&MVs differed histologically from MNs by their higher cellularity and presence of larger spindled or epithelioid cells with vesicular nuclei. Immunohistochemically, the tumor cells expressed CIV (9 of 10), calponin (7 of 9), SMA (5 of 10), Leu-7 (1 of 7), S-100 protein (1 of 11), but not NGFR, GFAP, or CD34. EMA-positive spindled cells surrounded tumor fascicles in 1 case. Intralesional neuraxons were not identified. Clinically, these tumors differed from the MNs by exhibiting a male-to-female ratio of 4:7, a peak incidence in the 2nd decade, and an upper body distribution. Our results indicate that the MN shows NS differentiation and is the bona fide nerve sheath tumor, whereas the C&MVs fail to show convincing evidence of NS differentiation and probably warrant a separate classification.
与神经鞘黏液瘤(神经鞘黏液瘤的黏液样变体)相反,在所谓的细胞型和混合型(中间型)神经鞘黏液瘤中,神经支持细胞(NS)分化的证据仍存在争议。在本研究中,我们从武装部队病理研究所软组织登记处选取了22例编码为神经鞘黏液瘤或神经鞘瘤的肿瘤。每例肿瘤在组织学上被分为黏液样/细胞稀少型神经鞘黏液瘤(MN)(n = 11)或“细胞型”或“混合型”(中间型)神经鞘黏液瘤变体(C&MV)(n = 11),并进行免疫组织化学分析。MN由小的、细胞形态温和的细胞组成,这些细胞排列在疏松的细胞网络中或高度黏液样结节内的条索状结构中,结节由致密胶原界定。这些肿瘤通过对S-100蛋白(11例中的11例)、低亲和力神经生长因子受体p75(NGFR)(10例中的10例)呈现一致的免疫反应性,以及对胶质纤维酸性蛋白(GFAP)(11例中的10例)和CD57(Leu-7)(9例中的5例)呈现可变反应性,显示出明确的NS分化证据。它们还显示出细胞周围IV型胶原(CIV)表达(9例中的9例)、散在的瘤内CD34阳性梭形细胞(10例中的10例)、位于相邻致密胶原内的上皮膜抗原(EMA)阳性梭形细胞(11例中的8例),以及对α-平滑肌肌动蛋白(SMA)(10例中的3例)和钙调蛋白(9例中的4例)的免疫反应性。在4例中,通过博迪安组织化学方法或用抗神经丝蛋白进行免疫组织化学检测到散在的瘤内神经轴突。这些肿瘤的男女比例为6:5,发病高峰在生命的第四个十年,解剖分布包括上肢、下肢和背部。C&MV包括9例“混合型”和2例“细胞型”变体。C&MV在组织学上与MN不同,其细胞密度更高,存在较大的梭形或上皮样细胞,核呈泡状。免疫组织化学方面,肿瘤细胞表达CIV(10例中的9例)、钙调蛋白(9例中的7例)、SMA(10例中的5例)、Leu-7(7例中的1例)和S-100蛋白(11例中的1例),但不表达NGFR、GFAP或CD34。1例中EMA阳性梭形细胞围绕肿瘤束。未发现瘤内神经轴突。临床上,这些肿瘤与MN不同,男女比例为4:7,发病高峰在第二个十年,且分布在上半身。我们的结果表明,MN显示NS分化,是真正的神经鞘肿瘤,而C&MV未能显示令人信服的NS分化证据,可能需要单独分类。